Comparative Pharmacology
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus ZTALMY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMPT PHENYTOIN SODIUM versus ZTALMY.
PROMPT PHENYTOIN SODIUM vs ZTALMY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, thereby reducing repetitive firing of action potentials and inhibiting the spread of seizure activity.
Ganaxolone is a positive allosteric modulator of GABAA receptors, acting at extrasynaptic and synaptic receptors to enhance chloride ion conductance and inhibit neuronal excitability.
Loading dose: 15-20 mg/kg (max 1500 mg) IV at a rate not exceeding 50 mg/min. Maintenance dose: 300-600 mg/day IV or orally in 3 divided doses. Adjust per therapeutic drug monitoring (target total phenytoin 10-20 mcg/mL).
Initial: 5 mg orally once daily for 7 days; titrate by 5 mg/day every 7 days to a maintenance dose of 30 mg once daily. Maximum: 30 mg daily.
None Documented
None Documented
30-100 hours (average 40 hours) following IV administration; prolonged in hepatic impairment, neonates, and with enzyme inhibitors; shorter in children and with enzyme inducers.
Terminal elimination half-life is approximately 30 hours (range 20-40 hours) in adults, supporting once-daily dosing. Steady-state is achieved within 5-7 days.
Primarily hepatic metabolism (CYP2C9) to inactive p-HPPH. Renal excretion as p-HPPH glucuronide (~60-70%) and unchanged drug (5%), with ~30% biliary/fecal elimination.
Primarily hepatic metabolism via glucuronidation and oxidation; <1% excreted unchanged in urine. Fecal elimination accounts for approximately 90% of the administered dose, with <5% in urine.
Category D/X
Category C
Anticonvulsant
Anticonvulsant